Declaration of Voting Results & Voting Rights Announcements • Jul 31, 2023
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Through the rights issue, carried out in June 2023, the number of outstanding shares and votes has increased by 6,265,892, from 22,680,408 to 28,946,300. The share capital has increased by SEK 6,265,892, from SEK 22,680,408 to SEK 28,946,300.
Kerstin Hasselgren Chief Financial Officer Xspray Pharma AB Mob: +46 (0) 70 311 16 83 E-mail: [email protected]
Xspray Pharma AB (publ) is a pharmaceutical company with numerous product candidates in clinical development, utilizing its innovative, patented HyNap-technology to create improved versions of marketed protein kinase inhibitors (PKI), the largest oncology segment often with high drug prices. The company's goal is to become a market leader of enhanced PKIs for cancer treatment. Xspray Pharma's primary drug candidate, Dasynoc (XS004-dasatinib), is currently undergoing FDA review. It is an amorphous form of dasatinib, demonstrating bioequivalence at a 30% lower dose because of better solubility profile. Its compatibility with proton pump inhibitors (PPIs), commonly co-prescribed to chronic myeloid leukemia patients, provides a significant advantage. Xspray Pharma is building a robust product portfolio, including XS003-nilotinib (an optimized version of Tasigna®) and XS008-axitinib (an optimized version of Inlyta®).
Xspray Pharma's shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). www.xspraypharma.com
This information is information that Xspray Pharma AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023- 07-31 11:40 CEST.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.